Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Simcere Approved to Start China Trial of Gout Treatment

publication date: Dec 2, 2020

Simcere Pharma of Nanjing was approved to start China trials of a novel treatment for gout. URC102 is a selective inhibitor of uric acid transporter (URAT-1). One year ago, Simcere entered a $70 million agreement for China rights to URC102 from JW Pharma of Korea. In a Korea Phase IIa trial, the candidate was effective and well-tolerated. Present therapies for gout have side effects that limit their usefulness, the companies said. More details....

Stock Symbols: (HK: 2096) (KRX: 001060)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.